Neurofibromatosis Type1, Type 2, Tuberous Sclerosis and Von Hippel-Lindau Disease

Overview

Journal Childs Nerv Syst

Specialty Pediatrics

Date 2023 Oct 11

PMID 37819506

Authors

M Elbeltagy

M Abbassy

Affiliations

Soon will be listed here.

Abstract

Neurocutaneous syndromes (also known as phakomatoses) are heterogenous group of disorders that involve derivatives of the neuroectoderm. Each disease has diagnostic and pathognomonic criteria, once identified, thorough clinical examination to the patient and the family members should be done. Magnetic resonance imaging (MRI) is used to study the pathognomonic findings withing the CNS (Evans et al. in Am J Med Genet A 152A:327-332, 2010). This chapter includes the 4 most common syndromes faced by neurosurgeons and neurologists; neurofibromatosis types 1 and 2, tuberous sclerosis and Von Hippel-Lindau disease. Each syndrome has specific genetic anomaly that involves a tumor suppressor gene and the loss of inhibition of specific pathways. The result is a spectrum of cutaneous manifestations and neoplasms.

References

Evans D, Howard E, Giblin C, Clancy T, Spencer H, Huson S . Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service. Am J Med Genet A. 2010; 152A(2):327-32. DOI: 10.1002/ajmg.a.33139. View

Rasmussen S, Yang Q, Friedman J . Mortality in neurofibromatosis 1: an analysis using U.S. death certificates. Am J Hum Genet. 2001; 68(5):1110-8. PMC: 1226092. DOI: 10.1086/320121. View

Cawthon R, Weiss R, Xu G, Viskochil D, Culver M, Stevens J . A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell. 1990; 62(1):193-201. DOI: 10.1016/0092-8674(90)90253-b. View

DeClue J, Papageorge A, Fletcher J, Diehl S, Ratner N, Vass W . Abnormal regulation of mammalian p21ras contributes to malignant tumor growth in von Recklinghausen (type 1) neurofibromatosis. Cell. 1992; 69(2):265-73. DOI: 10.1016/0092-8674(92)90407-4. View

Davies H, Bignell G, Cox C, Stephens P, Edkins S, Clegg S . Mutations of the BRAF gene in human cancer. Nature. 2002; 417(6892):949-54. DOI: 10.1038/nature00766. View

Pfister S, Janzarik W, Remke M, Ernst A, Werft W, Becker N . BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest. 2008; 118(5):1739-49. PMC: 2289793. DOI: 10.1172/JCI33656. View

Kaul A, Chen Y, Emnett R, Dahiya S, Gutmann D . Pediatric glioma-associated KIAA1549:BRAF expression regulates neuroglial cell growth in a cell type-specific and mTOR-dependent manner. Genes Dev. 2012; 26(23):2561-6. PMC: 3521628. DOI: 10.1101/gad.200907.112. View

Gutmann D . Using neurofibromatosis-1 to better understand and treat pediatric low-grade glioma. J Child Neurol. 2008; 23(10):1186-94. PMC: 2581748. DOI: 10.1177/0883073808321061. View

Carey J, Laub J, Hall B . Penetrance and variability in neurofibromatosis: a genetic study of 60 families. Birth Defects Orig Artic Ser. 1979; 15(5B):271-81. View

10.

North K . Neurofibromatosis type 1: review of the first 200 patients in an Australian clinic. J Child Neurol. 1993; 8(4):395-402. DOI: 10.1177/088307389300800421. View

11.

Crawford A, Schorry E . Neurofibromatosis update. J Pediatr Orthop. 2006; 26(3):413-23. DOI: 10.1097/01.bpo.0000217719.10728.39. View

12.

Messiaen L, Callens T, Mortier G, Beysen D, Vandenbroucke I, van Roy N . Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat. 2000; 15(6):541-55. DOI: 10.1002/1098-1004(200006)15:6<541::AID-HUMU6>3.0.CO;2-N. View

13.

Koczkowska M, Callens T, Gomes A, Sharp A, Chen Y, Hicks A . Expanding the clinical phenotype of individuals with a 3-bp in-frame deletion of the NF1 gene (c.2970_2972del): an update of genotype-phenotype correlation. Genet Med. 2018; 21(4):867-876. PMC: 6752285. DOI: 10.1038/s41436-018-0269-0. View

14.

Lee W, Teckie S, Wiesner T, Ran L, Prieto Granada C, Lin M . PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors. Nat Genet. 2014; 46(11):1227-32. PMC: 4249650. DOI: 10.1038/ng.3095. View

15.

Duffner P, Cohen M, Seidel F, Shucard D . The significance of MRI abnormalities in children with neurofibromatosis. Neurology. 1989; 39(3):373-8. DOI: 10.1212/wnl.39.3.373. View

16.

North K, Joy P, Yuille D, Cocks N, Mobbs E, Hutchins P . Specific learning disability in children with neurofibromatosis type 1: significance of MRI abnormalities. Neurology. 1994; 44(5):878-83. DOI: 10.1212/wnl.44.5.878. View

17.

Brems H, Chmara M, Sahbatou M, Denayer E, Taniguchi K, Kato R . Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype. Nat Genet. 2007; 39(9):1120-6. DOI: 10.1038/ng2113. View

18.

Wimmer K, Etzler J . Constitutional mismatch repair-deficiency syndrome: have we so far seen only the tip of an iceberg?. Hum Genet. 2008; 124(2):105-22. DOI: 10.1007/s00439-008-0542-4. View

19.

Ejarque I, Millan-Salvador J, Oltra S, Pesudo-Martinez J, Beneyto M, Perez-Aytes A . [Arnold-Chiari malformation in Noonan syndrome and other syndromes of the RAS/MAPK pathway]. Rev Neurol. 2015; 60(9):408-12. View

20.

Fisher E, Vuzevski V . Cytogenesis of schwannoma (neurilemoma), neurofibroma, dermatofibroma, and dermatofibrosarcoma as revealed by electron microscopy. Am J Clin Pathol. 1968; 49(2):141-54. DOI: 10.1093/ajcp/49.2.141. View